CorMedix Inc. Announces Commercial and Reimbursement Updates
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced updates related to its business and anticipated launch of DefenCath®.
Related news for (CRMD)
- CorMedix Announces Strategic Minority Investment in Talphera
- URGENT VENU Update + 52-Week High Movers
- Breaking News: MoBot’s Latest Update as of 05/06/25 02:00 PM
- CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
- Breaking News: MoBot’s Latest Update as of 05/06/25 01:00 PM